Form 4: RxSight Director Jesse Corley Granted 10,752 Restricted Stock Units

RxSight, Inc. Director Jesse Anderson Corley was granted 10,752 restricted stock units (RSUs) on June 3, 2025, as part of his compensation, aligning his interests with shareholders.

Summary

• Jesse Anderson Corley, a Director at RxSight, Inc. (RXST), acquired 10,752 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 3, 2025.
• Each RSU represents a contingent right to receive one share of RxSight, Inc. Common Stock.
• The RSUs are subject to a vesting schedule where 100% will vest on the earlier of the one-year anniversary of the grant date (June 3, 2025) or the date immediately prior to the next annual meeting of stockholders following the grant date.
• Vesting is contingent upon Mr. Corley's continued service as an Outside Director.
• Following this transaction, Mr. Corley directly beneficially owns 49,190 shares of Common Stock.
• Additionally, Mr. Corley has indirect beneficial ownership of 3,210 shares held by his spouse, 474,141 shares held by the Andy Corley Living Trust (for which he serves as trustee), 7,083 shares held by The Corley Foundation, and 18,708 shares held by the Juana McKay Living Trust (for which his spouse serves as trustee).

Sentiment

Score: 7

Explanation: The sentiment is positive as it represents a standard equity grant to a director, aligning their interests with the company's long-term performance. It does not indicate any negative operational or financial news.

Positives

• The grant of Restricted Stock Units to Director Jesse Corley aligns his financial interests directly with the long-term performance and shareholder value of RxSight, Inc.
• Equity-based compensation is a standard practice for retaining and incentivizing key management and directors, signaling commitment to the company's future.

Negatives

• No specific negative aspects are identified within this Form 4 filing, as it primarily reports a routine compensation grant.

Risks

• The vesting of the granted RSUs is contingent on Jesse Corley's continued service as an Outside Director, meaning the shares could be forfeited if his directorship ceases before the vesting conditions are met.

Future Outlook

The grant of Restricted Stock Units to Director Jesse Corley includes a vesting schedule that extends into the future, with 100% vesting on the earlier of June 3, 2026 (one-year anniversary of grant) or the date immediately prior to the next annual meeting of stockholders following the grant date, subject to his continued service.

Industry Context

This Form 4 filing reflects a standard practice of providing equity compensation to directors in publicly traded companies, particularly in the medical technology or ophthalmology sector where RxSight operates. Such grants are common mechanisms to align director incentives with long-term company performance and shareholder returns.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a common form of equity compensation across various industries, including medical technology. Companies like Alcon (ALC), Bausch + Lomb (BLCO), and Johnson & Johnson (JNJ) often utilize similar equity-based incentives for their non-employee directors to foster long-term alignment.
• The vesting schedule, tied to continued service and a one-year anniversary or next annual meeting, is typical for director RSU grants, aiming to retain experienced board members.

Related Party Transactions

• Jesse Corley's indirect beneficial ownership includes shares held by the Andy Corley Living Trust, for which he serves as trustee.
• Indirect beneficial ownership also includes shares held by The Corley Foundation, where Mr. Corley may be deemed to share voting and investment power.
• Shares held by the Juana McKay Living Trust are indirectly beneficially owned, for which Mr. Corley's spouse serves as trustee.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholder value creation, as the value of his compensation is tied to the company's stock performance.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Management: Reinforces the compensation structure for non-employee directors, which is part of overall corporate governance.

Next Steps

• The 10,752 Restricted Stock Units granted to Jesse Corley are expected to vest on the earlier of June 3, 2026, or the date immediately prior to the next annual meeting of stockholders following the grant date, provided he continues as an Outside Director.

Key Dates

Keywords

RxSight, RXST, Form 4, SEC filing, Restricted Stock Units, RSU, insider transaction, director compensation, equity grant, beneficial ownership